Pacer Advisors Inc. Has $4.20 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX

Pacer Advisors Inc. boosted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 121.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,621 shares of the company’s stock after purchasing an additional 16,257 shares during the period. Pacer Advisors Inc.’s holdings in Neurocrine Biosciences were worth $4,201,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. USA Financial Formulas bought a new stake in shares of Neurocrine Biosciences during the fourth quarter worth $25,000. DJE Kapital AG acquired a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at $28,000. Geneos Wealth Management Inc. boosted its holdings in shares of Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares in the last quarter. Meeder Asset Management Inc. grew its position in Neurocrine Biosciences by 651.6% during the 4th quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock worth $33,000 after acquiring an additional 202 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new stake in Neurocrine Biosciences during the 4th quarter worth $39,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Activity at Neurocrine Biosciences

In related news, Director Kevin Charles Gorman sold 245,088 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $154.33, for a total value of $37,824,431.04. Following the transaction, the director directly owned 511,293 shares of the company’s stock, valued at $78,907,848.69. The trade was a 32.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jude Onyia sold 11,000 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $160.25, for a total value of $1,762,750.00. Following the completion of the transaction, the insider directly owned 25,846 shares in the company, valued at approximately $4,141,821.50. This represents a 29.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 355,234 shares of company stock valued at $55,330,060 over the last ninety days. Insiders own 4.60% of the company’s stock.

Neurocrine Biosciences Trading Up 2.1%

Shares of NBIX opened at $161.62 on Tuesday. The stock’s 50-day moving average price is $149.13 and its two-hundred day moving average price is $140.84. Neurocrine Biosciences, Inc. has a 12 month low of $122.14 and a 12 month high of $169.57. The company has a market capitalization of $16.25 billion, a PE ratio of 24.90, a PEG ratio of 1.19 and a beta of 0.39.

Wall Street Analyst Weigh In

Several equities analysts have commented on NBIX shares. HC Wainwright increased their target price on Neurocrine Biosciences from $192.00 to $215.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Truist Financial boosted their price target on Neurocrine Biosciences from $140.00 to $155.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. The Goldman Sachs Group initiated coverage on Neurocrine Biosciences in a research note on Tuesday, June 2nd. They issued a “buy” rating and a $213.00 price objective for the company. Wolfe Research initiated coverage on shares of Neurocrine Biosciences in a research report on Tuesday, February 24th. They set an “outperform” rating and a $160.00 target price on the stock. Finally, Royal Bank Of Canada boosted their target price on shares of Neurocrine Biosciences from $180.00 to $183.00 and gave the stock an “outperform” rating in a report on Friday, May 29th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $187.52.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.